Patents Assigned to GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
  • Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
    Patent number: 11440903
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 13, 2022
    Assignees: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng Long, Yang Zhang, Zhengxia Chen, Xiaoxin Chen, Zhuowei Liu, Meibi Dai, Zhiqiang Liu, Shuhui Chen
  • SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20210087181
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Application
    Filed: October 30, 2018
    Publication date: March 25, 2021
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng LONG, Yang ZHANG, Zhengxia CHEN, Xiaoxin CHEN, Zhuowei LIU, Meibi DAI, Zhiqiang LIU, Shuhui CHEN
  • FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20200062716
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Applicant: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
    Inventors: Zhengxia CHEN, Chaofeng LONG, Yang ZHANG, Xiaoxin CHEN, Yikai WANG, Meibi DAI, Zhuowei LIU, Haixia ZHAO, Xing LIU, Guoping HU, Jian LI, Shuhui CHEN
  • Histone deacetylase inhibitor, and preparation method and use thereof
    Patent number: 10532053
    Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 14, 2020
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Lijuan Chen, Chaofeng Long, Xiaoxin Chen, Zhuowei Liu, Haoyu Ye, Chenshi Xie
  • Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
    Patent number: 10494373
    Abstract: Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 3, 2019
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Xile Liu, Linxia Xiao, Chao Ding, Fei Wang, Jian Li
  • Hydroxyl purine compounds and applications thereof
    Patent number: 10098885
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 16, 2018
    Assignee: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen
  • Quinoline derivatives as SMO inhibitors
    Patent number: 9938292
    Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Hao Wu, Chaofeng Long, Jun Lin, Xiaoxin Chen, Yunhui Li, Zhuowei Liu, Changqing Wei, Lijuan Chen, Shuhui Chen
  • HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF
    Publication number: 20170326149
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Application
    Filed: September 22, 2015
    Publication date: November 16, 2017
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, MEDSHINE DISCOVERY INC.
    Inventors: Lingyun WU, Chaofeng LONG, Peng ZHANG, Xiaoxin CHEN, Li ZHANG, Zhuowei LIU, Jian LI, Shuhui CHEN